Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL959117 | 0.86 | MAPT (0.49) | MRGPRX4SCN9AFFAR4ALDH1A1POLB | |
| SCHEMBL962006 | 0.84 | GPR52 (0.48) | MRGPRX4SCN9AFFAR4 | |
| SCHEMBL959319 | 0.84 | MRGPRX4 (0.61) | MRGPRX4L3MBTL1PTGER1 | |
| SCHEMBL958823 | 0.83 | MRGPRX4 (0.49) | MRGPRX4SCN9AFFAR4ALDH1A1POLB | |
| SCHEMBL962201 | 0.82 | MRGPRX4 (0.53) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL960377 | 0.81 | P2RX7 (0.40) | MRGPRX4SCN9AFFAR4ALDH1A1HPGD | |
| SCHEMBL959343 | 0.80 | MRGPRX4 (0.53) | MRGPRX4ALDH1A1POLBGAAHPGD | |
| SCHEMBL957915 | 0.80 | MRGPRX4 (0.50) | MRGPRX4SCN9AALDH1A1POLBGAA | |
| SCHEMBL958072 | 0.76 | L3MBTL1 (0.51) | MRGPRX4ALDH1A1GAAL3MBTL1 | |
| SCHEMBL961250 | 0.75 | GPR52 (0.56) | MRGPRX4SCN9AFFAR4POLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2253618-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | Takeda Pharmaceutical Company Limited (JP) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009421-A1 | COMPOUND HAVING 6-MEMBERED AROMATIC RING | GPR4, NR3C2, NR5A2 | MRGPRX4 133/4885SCN9A 1152/4885FFAR4 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.